Table 2.

Proportion of patients achieving minimal clinically important difference (change ≥ 4 from baseline to end point) at end point (week 12, last observation carried forward) in the international index of erectile function erectile function domain^*

Variable	PRN						OAD
	Low dose (10 mg; n = 527)			High dose (20 mg; n = 1,816)			Low dose (2.5 mg; n = 96)			High dose (5 mg; n = 617)
	N	n	OR (TAD vs PBO)	N	n	OR (TAD vs PBO)	N	n	OR (TADA vs PBO)	N	n	OR (TAD vs PBO)
Age (y)
<50	139	96	3.34§	597	456	4.24§	21*	13	3.00†	191	151	5.27§
50–64	219	146	5.20§	813	613	6.72§	35*	22	4.25§	299	207	4.65§
≥65	128	82	4.99§	298	217	6.56§	37*	16	2.47	103	68	6.22§
Baseline BMI (kg/m2)
<30	408	279	4.68§	1,368	1,027	5.70§	71	42	3.84§	427	314	5.64§
≥30	78	45	3.47§	341	260	5.73§	22*	9	1.37	166	112	3.62§
Baseline diabetes
Yes	88	51	3.93§	372	246	4.41§	17*	9	3.78†	93	55	3.78§
No	398	273	4.61§	1,337	1,041	6.30§	76	42	2.99§	500	371	5.34§
Baseline cardiovascular disorder
Yes	174	100	3.32§	596	434	5.51§	47*	26	3.70§	244	163	5.15§
No	312	224	5.36§	1,113	853	5.79§	46*	25	2.31†	349	263	4.88§
Baseline hypertension
Yes	127	68	2.80§	477	345	5.35§	38*	18	2.84†	193	126	4.90§
No	359	256	5.36§	1,232	942	5.87§	55*	33	3.04§	400	300	5.00§
Baseline hyperlipidemia
Yes	59†	42	6.05§	193	141	5.77§	23*	12	3.64†	105	72	5.92§
No	427	282	4.30§	1,516	1,146	5.69§	70	39	2.86§	488	354	4.70§
Smoking
Yes	144	100	4.32§	455	346	4.94§	11*	5	1.04	81	58	2.44†
No	342	224	4.50§	1,247	937	6.02§	82	46	3.50§	210	148	5.57§
Alcohol use
Yes	286	197	5.07§	893	681	6.28§	66	34	2.95§	235	172	5.62§
No	200	127	3.87§	804	597	5.20§	27*	17	2.94†	114	79	3.03§

BMI = body mass index; N = number of subjects with baseline and end-point results; n = number of subjects achieving minimal clinically important difference at study end point; PBO = placebo; OAD = once a day; OR = odds ratio; PRN = as needed; TAD = tadalafil.

^*Fewer than 64 patients in subgroup.

^†P ≤ .05.

^§P ≤ .001.